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Received 5 January 2016; revised 25 February 2016; accepted 29 February 2016AbstractObjective: To evaluate the efficacy and safety of intratympanic and systemic steroid therapies in the initial treatment of Sudden Sensorineural
Hearing Loss (SSNHL) patients.
Methods: A comprehensive search of PubMed, Wanfang database and CNKI (China National Knowledge Infrastructure) was performed covering
the period from January 1990 to July 2014. A meta-analysis was conducted after filtering by the criteria of Cochrane Collaboration. Three
hundred fifty six subjects in nine studies allocated to the group of intratympanic steroid therapies and 343 controls receiving systemic steroid
therapies met the criteria for meta-analysis. The data were extracted and analyzed using the RevMan 5.3 meta-analysis software.
Results: The total effectiveness rate in SSNHL patients receiving intratympanic steroid therapies did not differ statistically from patients
receiving systemic therapies (RR ¼ 1.08, 95％CI ¼ 0.99e1.99, P ¼ 0.10), although the rate of full hearing recovery in this group differed
significantly from patients receiving systemic therapies (RR ¼ 1.29, 95％CI ¼ 1.00e1.66, P ¼ 0.05).
Conclusion: Local steroid therapy appears to generate higher rate of complete hearing recovery than systemic steroid treatment as an initial
treatment for SSNHL, which may be especially useful for patients in whom systemic steroids are contraindicated.
Copyright © 2016, PLA General Hospital Department of Otolaryngology Head and Neck Surgery. Production and hosting by Elsevier
(Singapore) Pte Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Sudden Sensorineural Hearing Loss (SSNHL), first re-
ported by De Kleyn (Seggas et al., 2010) in 1944, is an oto-
logic event that needs urgent intervention. SSNHL is
commonly defined as hearing loss greater than 30 dB and
involving at least 3 consecutive audiometric frequencies,
occurring within 3 days without any identifiable cause (Seggas* Corresponding author. Department of Clinical Science, Intervention and
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Pte Ltd. This is an open access article under the CC BY-NC-ND license (http://cret al., 2010; Arastou et al., 2013). Although a number of
theories regarding the cause have been suggested, the etiol-
ogies and pathogenesis of SSNHL are still unclear. The overall
incidence of diagnosed SSNHL ranges from 5 to 20 per
100,000 persons per year (Seggas et al., 2010; Arslan et al.,
2011; Battaglia et al., 2008). The rate of spontaneous recov-
ery without treatment ranges 32e65% (Seggas et al., 2010;
Arastou et al., 2013; Battaglia et al., 2008), and the rate of
full recovery in treated patients ranges 49e79% (Arastou
et al., 2013; Battaglia et al., 2008).
The cause of SSNHL has been the subject of debate for many
years and has been widely studied. The suggested theories
include vascular compromise, viral infection, and immune-
mediated reactions (Seggas et al., 2010; Arslan et al., 2011).
The condition may well have a multifactorial etiology and eachgy Head and Neck Surgery. Production and hosting by Elsevier (Singapore)
eativecommons.org/licenses/by-nc-nd/4.0/).
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proportion of the total number of observed cases.
A number of treatments have been reported, such as
vasoactive substances, hyperbaric oxygen, antivirals and vi-
tamins (Crane et al., 2014; Koltsidopoulos et al., 2013). Each
approach has, however, been debated with no standard pro-
tocol universally accepted until the introduction of steroid
therapy. Administration of steroids, systemically or intra-
tympanally, alone or in combination, is considered to be the
mainstay of treatment for SSNHL (Arslan et al., 2011;
Battaglia et al., 2008; Crane et al., 2014). Systemic steroid
therapy, however, has serious adverse effects and contraindi-
cations and therefore local use of steroids has attracted
popularity among otology centers during the last decade
(Koltsidopoulos et al., 2013).
In the present study we performed a review of randomized
controlled trials (RCTs) involving the use of intratympanic
steroid therapy (IST) or systemic steroid therapy (SST) for
initial treatment in SSNHL patients. The aim of the meta-
analysis was to evaluate the efficacy and safety of IST and
determine whether this treatment is more effective as a pri-
mary treatment for SSNHL than SST.
2. Materials and methods2.1. Strategy and criteriaLiterature search was performed using a combination of the
keywords “sudden hearing loss”, “hearing loss”, ‘‘steroid’’,
“transtympanic” and ‘‘intratympanic’’. PubMed, Wanfang
database and CNKI were searched to yield all possible rele-
vant results. Articles limited to human subjects and published
in the English or Chinese languages between January 1990 and
July 2014 were included. All RCTs based on the use of ste-
roids and the efficacies of intratympanic and systemic steroid
treatments in patients with SSNHL were assessed. Two au-
thors collected and extracted the data independently. Dis-
agreements were solved through discussion. RCTs fulfilling
the following criteria were included: (1) the RCTwas designed
to study the efficacy and safety of SST and IST as initial
treatment of SSNHL; (2) SSNHL was reliably diagnosed,
excluding other causes, and the RCT presented with a control
arm (systemic steroid treatment) and a treatment armTable 1
Characteristics of the included research.
Included literature
(author, published time)
Intratympanic therapy
Drug Usage and dosage
Lim et al. (2013) Dexamethasone Intratympanic injection, 1.5e2 m
Rauch et al. (2011) Methylprednisolone Intratympanic injection, 40 mg
Dispenza et al. (2011) Dexamethasone Intratympanic injection, 4 mg
Zhou et al. (2006) Dexamethasone Intratympanic injection, 2.5 mg
Peng et al. (2008) Dexamethasone Intratympanic injection, 5 mg
Deng (2011) Dexamethasone Intratympanic injection, 1 mg
Yi et al. (2011) Dexamethasone Auditory tube injection, 5 mg
You et al. (2008) Dexamethasone Intratympanic injection, 1e1.5 m
Mao et al. (2005) Methylprednisolone Auditory tube injection, 5 mg(intratympanic steroids), as well as a clear description of the
steroid treatment regimen; (3) the age and sex in the treatment
and control groups were not limited, but with no significant
difference at baseline.
Data fulfilling the following criteria were excluded: (i) ar-
ticles that were reviews, expert commentaries, case reports or
other non-clinical research literature, (ii) trials that had
incomplete reporting of pre- and post-treatment PTA results,
(iii) trials that did not evaluate steroids as a primary treatment
of SSNHL, and did not evaluate systemic steroids alone or
intratympanic steroids alone as the primary treatment.
Nine studies met the criteria and were included for analysis
(Table 1). The following information was extracted from each
article: sample size of each study arm, type and dose of ste-
roids, methods of steroid administration, duration of therapy,
outcomes, major complications and follow-up time.
After identifying the reports, the abstract and full text were
carefully read and the publication's quality was screened and
evaluated according to the Handbook of System Quality
Evaluation of Cochrane criteria. Pre- and post-treatment pure-
tone audiometry (PTA) results were noted. Treatment efficacy
was determined in accordance to the sudden deafness diag-
nosis and treatment standards by the Chinese Medical Asso-
ciation Otolaryngology Head and Neck Surgery Branch,
Ji'nan, 2005. A change of hearing thresholds within the
250e4000 Hz frequency range back to within normal range, or
to the level of the healthy ear, or back to the level before
SSNHL was considered to represent a full recovery (cured);
and a threshold recovery of 15 dB or greater was considered to
indicate significant improvement (Spear and Schwartz, 2011).
The rates of full recovery and significant improvements were
calculated.2.2. Statistical analysisData analysis was performed with the RevMan5.3 software.
Tests of heterogeneity were conducted with the chi-square test,
as an x2 variate. Between-study heterogeneity was assessed
using the I2, as the percentage of variability among effect
estimates beyond that expected by chance (Ng et al., 2014). As
a reference, I2 values of 25% were considered low, 50% as
moderate, and 75% as high (Ng et al., 2014). If the result did
not show heterogeneity (i.e. I2< 50%, P > 0.10), the fixed-Systemic therapy Follow-up
time
Time Drug Usage and dosage Time
g 2w Prednisone Oral, 60 mg/d 10d 3w
2w Prednisone Oral, 60 mg/d 19d 6m
4w Prednisone Oral, 6 mg/d 14d 6m
8d Prednisone Oral, 30 mg/d 8d 20d
10d Dexamethasone Intravenous, 10 mg 10d 20d
10d Dexamethasone Intravenous, 10 mg 10d 30d
10d Dexamethasone Intravenous,10 mg 7d 30d
g 10d Dexamethasone Intravenous, 10 mg 10d 15d
10d Methylprednisolone Intravenous, 40 mg 7d 20d
Fig. 2. Meta-analysis funnel plot of local and systemic glucocorticoid treat-
ment for SSNHL.
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neity existed, the random-effects mode was used. The Man-
teleHaenszel method was used to summarize the results, by
calculation of the combined Risk Ratio (RR) and 95% confi-
dence intervals (95% CI), and forest plots were generated.
3. Results
Nine studies met the inclusion criteria and revealed rates of
significant improvement and full recovery. The nine studies
were published from 2005 to 2013. For intratympanic therapies,
dexamethasone (Lim et al., 2013; Dispenza et al., 2011; Zhou
et al., 2006; Peng et al., 2008; Deng, 2011; Yi et al., 2011;
You et al., 2008) and methylprednisolone (Rauch et al., 2011;
Mao et al., 2005) were used, either through the tympanic
membrane (Lim et al., 2013; Rauch et al., 2011; Dispenza et al.,
2011; Zhou et al., 2006; Peng et al., 2008;Deng, 2011;You et al.,
2008) or via the auditory tube (Yi et al., 2011; Mao et al., 2005).
The drugs administered systemically were prednisone (Lim
et al., 2013; Rauch et al., 2011; Dispenza et al., 2011; Zhou
et al., 2006), dexamethasone (Peng et al., 2008; Deng, 2011;
Yi et al., 2011; You et al., 2008) and methylprednisolone
(Mao et al., 2005), via oral (Lim et al., 2013; Rauch et al., 2011;
Dispenza et al., 2011; Zhou et al., 2006) or intravenous (Peng
et al., 2008; Deng, 2011; Yi et al., 2011; You et al., 2008; Mao
et al., 2005) routes. Data from the nine studies were pooled
for meta-analysis.
A forest plot was created to depict the results of individual
studies along with the summary results derived from the meta-
analyses. Results showed that patients who received intra-
tympanic steroids therapies demonstrated a statistically signif-
icant improvement in the hearing threshold as compared to those
receiving systemic steroids therapies, reflecting that local ste-
roids treatments for SSNHL was more effective than systemic
therapies. Fig. 1 presents the rate of total effectiveness for local
steroids treatments in comparison to systemic steroids treat-
ments. The forest plot results are: x2 ¼ 12.15, p ¼ 0.14,
I2 ¼ 34%. As can be seen from the figure, I2 ¼ 34% < 50%,
P¼ 0.14> 0.10, indicates no heterogeneity and justification for
using the fixed-effect model. The ManteleHaenszel method
was used to summarize the results. The total Risk Ratio (RR)
was 1.08 and the 95% confidence intervals (95% CI) was
0.99e1.19. The overall effect, Z¼ 1.67, P¼ 0.10> 0.05, did notFig. 1. Meta-analysis forest map of the rate of significant improvemeindicate statistically significant difference between the rates of
total effectiveness for local and systemic steroids therapies.
Fig. 2 presents the funnel plots of local and systemic steroids
treatments. In the funnel plot, each point is distributed sym-
metrically, indicating low publication bias. Fig. 3 compares the
rates of full recovery for local and systemic steroids treatments.
The forest plot results are x2 ¼ 5.19, p ¼ 0.64, I2 ¼ 0%. The
figure shows I2¼ 0% < 50%, P¼ 0.64 > 0.10, again indicating
no heterogeneity and justification for using the fixed-effect
model. The ManteleHaenszel method showed that the total
RRwas 1.29 and the 95%CI was 1.00e1.66. The overall effect,
Z ¼ 1.95, P ¼ 0.05 ¼ 0.05, showed a statistically significant
difference. Fig. 4 presents a funnel plot of the number of patients
with full recovery. Each point in the funnel plot is distributed
symmetrically, indicating low publication bias.
Side effects of intratympanic and systemic steroid therapies
were reported in six (Rauch et al., 2011; Dispenza et al., 2011;
Deng, 2011; Yi et al., 2011; You et al., 2008; Mao et al., 2005)
of the nine studies. Complications of transtympanic steroid
therapy included vertigo, otalgia, nystagmus, otitis media,
tinnitus, injection site pain, and persistent tympanic membrane
perforations. Of the 269 patients in these studies, 4 developed
vertigo (Deng, 2011), of whom 3 resolved spontaneously, one
was unable to stand upright and discontinued the treatment.
Persistent tympanic membrane perforation was seen in 5nt for local and systemic glucocorticoid treatments for SSNHL.
Fig. 3. Meta-analysis forest map of the rate of full recovery for local and systemic glucocorticoid treatments for SSNHL.
Fig. 4. Meta-analysis funnel plot of articles of local and systemic glucocor-
ticoid treatments for SSNHL depicting the number of patients with full
recovery.
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otitis media (Rauch et al., 2011). Two patients in the intra-
tympanic treatment group withdrew consent due to injection
site pain (Rauch et al., 2011). No infectious complications
occurred. Adverse reactions of systemic steroids use were
cardiovascular, gastrointestinal, neurologic, and endocrine
problems. Of the 256 patients in these studies, 13 developed
gastrointestinal problems (Deng, 2011; Yi et al., 2011; Mao
et al., 2005), 2 had insomnia (You et al., 2008), 6 had
elevated blood sugar levels (Deng, 2011; Yi et al., 2011), 3
showed elevated blood pressure levels (Deng, 2011; Yi et al.,
2011), and 1 developed weight gain (You et al., 2008). Otitis
media occurred in 1 patient (Rauch et al., 2011) and 1 patient
suffered right femoral head necrosis (Mao et al., 2005), the
latter being the most serious complication showed in Fig. 5).
No other serious complications occurred in the two groups.
4. Discussion
Treatment strategies for SSNHL vary widely and remain a
challenge for otologists. Since 1980, administration of cortico-
steroids (systemic and/or intratympanic) has been the mainstay
therapy for SSNHL (Battaglia et al., 2008; Koltsidopoulos
et al., 2013; Stachler, 2012). However, there is a limited
amount of clinical data and the efficacy and safety of steroids
for treatment in SSNHL remain controversial.In the nine randomized controlled trials, the total effective-
ness of local steroids in treating SSNHL was similar to that of
systemic steroid therapies. In contrast, the rate of full recovery in
local steroid treatment was higher than that in systemic thera-
pies. Systemic steroids may increase the risks of important
adverse effects, such as femoral head necrosis, gastrointestinal
and endocrine problems, and weight gain. In the systemic ste-
roid group, a total of 29 patients suffered side effects. By com-
parison, 17 people had side effects in the local glucocorticoid
group. Systemic administration of steroids may have broad ef-
fects on body functions, including numerous adverse reactions,
especially in long-term use. Due to side effects from systemic
administration of steroids, intratympanic administration of
steroids has been utilized (Kakehata et al., 2006; Hong et al.,
2009). Local administration of steroids via the middle ear cav-
ity may act directly on the inner ear at a higher concentration,
without risks of systemic complications or cochlear dysfunc-
tionse advantages that may make it an ideal choice for SSNHL
in certain patient groups. Intratympanic steroid treatment has
been used in patients in whom systemic steroids are contra-
indicated; i.e., in patients with immunocompromising distur-
bances, diabetes, hypertension, peptic ulcer, and tuberculosis.
The number of clinical trials, meta-analyses and reviews
concerning steroid therapy for SSNHL is large world-wide with
no consistent conclusions. Studies on SSNHL patients have
shown efficacy for intratympanic steroids as an initial treatment
and as a salvage therapy for refractory patients (Hong et al.,
2009; Koltsidopoulos et al., 2013; Lee et al., 2011; Wu et al.,
2011), and when combined with systemic steroids (Arastou
et al., 2013; Arslan et al., 2011; Gundogan et al., 2013;
Kakehata et al., 2011). Seggas et al. (2010) carried out a study
to seek the most effective technique and optimal administration
schedule by examining the published literature regarding the
therapeutic value of each method of treatment. They concluded
that topical steroids can be a valuable solution for SSNHL pa-
tients who either cannot tolerate systemic steroid therapy or are
refractory to it. Ding et al. (2013) stated, in studies on SSNHL
patients with diabetes, that local steroids should be the first
treatment of choice. Thus, local steroid treatment has been
assumed to be a suitable alternative when there are medical
contraindications to oral prednisone administration. In another
study, Arastou et al. (2013) evaluated the efficacy of combined
intratympanic and systemic steroid therapies compared with
systemic steroid therapy alone in SSNHL patients with poor
a: side effects of intratympanic steroid therapy
Complications of
transtympanic 
steroid therapy
in 269 patients.
5 patients: Persistent 
tympanic membrane
perforation
6 patients: otitis 
media
2 patients: 
injection site pain
4 patients: vertigo
3 patients: healed 
spontaneously
1 patient: unable to 
stand upright
b: side effects of systemic steroid therapy
Complications of
systemic steroid
therapy in 256
patients
13 patients: 
gastrointestina
l problems
2 patients: 
insomnia
1 patient: 
femoral head 
necrosis
1 patient: otitis 
media
1 patient:
weight gain
3 patients:
elevated blood
pressure levels
6 patients:
elevated blood 
sugar levels
Fig. 5. Side effects from intratympanic and systemic steroid therapies.
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more than 70 dB, and a greater than 2-week delay between the
onset of hearing loss and initiation of therapy). It was concluded
that combined intratympanic and systemic steroid therapy
showed a higher efficacy than systemic prednisolone alone in
the treatment of SSNHL patients with poor prognosis. So
SSNHL patients with poor prognostic factors can considerchoosing combined intratympanic and systemic steroid thera-
pies. Ng et al. (2014) conducted a meta-analysis to evaluate the
efficacy of intratympanic steroids as a salvage treatment for
patients who have initial treatment failure with systemic ste-
roids. They showed salvage intratympanic steroids to be supe-
rior to no further treatment in patients who have failed systemic
steroids.
In the present meta-analysis, we systematically scrutinized
English and Chinese literature on systemic and local admin-
istration of corticosteroids in SSNHL patients. The systemic
corticosteroids administered in all trials by oral or intravenous
routes were prednisone, dexamethasone, and methylprednis-
olone at a dose of 30e60 mg/d (oral) or 10 mg/d (intravenous)
for 7e10 days. Intratympanic administration of steroids was
performed about four times during a 1 month treatment period,
at a dose of 1e40 mg/injection (dexamethasone) or 5 mg/in-
jection (methylprednisolone). Our meta-analysis showed that
the dose in intratympanic steroid treatment was considerably
lower compared to that in systemic administration.
The purpose of our meta-analysis was to evaluate the effi-
cacy and safety of intratympanic and systemic steroid therapies
in the initial treatment for patients with SSNHL. The study
showed that the two different treatment protocols, systemic and
local steroids, resulted in similar rates of hearing improvement
but were different in the rate of complete recovery. Moreover,
local steroids carried lower risks of side effects as compared to
systemic treatments. We therefore recommend transtympanic
steroid administration as an initial treatment for those in whom
initial systemic steroid treatment has failed.
Our meta-analysis has limitations. The type of steroids used
varied as well as the duration and dose of treatment (Table 1).
For example, dexamethasone was used in 8 studies and
methylprednisolone in the remaining study. The dose of
dexamethasone ranged from 1 to 5 mg, and the administration
schedule varied from once a week for 4 consecutive weeks to
daily administration for 8 or 10 consecutive days. Because of
the limited number of trials and the variability regarding
duration and dose, subgroup analyses, such as comparisons
between dexamethasone and methylprednisolone or between
transtympanic injections and administration via the auditory
tube, could not be performed.
Some trials contained a small number of patients. Despite
that most of these studies showed a statistically significant
benefit, it cannot be excluded that studies with a similar
sample size but with negative results did not reach enough
priority for publication. Furthermore, publication bias cannot
be completely ruled out, although the funnel plots showed a
low publication bias. However, larger RCTs are required to
definitely confirm this conclusion.
The present study showed a statistically significant differ-
ence between intratympanic and systemic steroid treatments
for SSNHL. Intratympanic steroid treatment is an effective
procedure that allows focused treatment of the ear of the
affected side only, a factor which can reduce pharmacological
interactions. Despite the risks for adverse effects such as
infection, residual tympanic perforation and vertigo, compli-
cations are less frequent than with systemic treatment.
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